Hebbar Nikhil, Burikhanov Ravshan, Shukla Nidhi, Qiu Shirley, Zhao Yanming, Elenitoba-Johnson Kojo S J, Rangnekar Vivek M
Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky.
Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.
Cancer Res. 2017 Aug 1;77(15):4039-4050. doi: 10.1158/0008-5472.CAN-16-1970. Epub 2017 Jun 16.
Primary tumors are often heterogeneous, composed of therapy-sensitive and emerging therapy-resistant cancer cells. Interestingly, treatment of therapy-sensitive tumors in heterogeneous tumor microenvironments results in apoptosis of therapy-resistant tumors. In this study, we identify a prostate apoptosis response-4 (Par-4) amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells following therapy-induced caspase cleavage of the tumor suppressor Par-4 protein. PAF caused apoptosis in cancer cells resistant to therapy and inhibited tumor growth. A VASA segment of Par-4 mediated its binding and degradation by the ubiquitin ligase Fbxo45, resulting in loss of Par-4 proapoptotic function. Conversely, PAF, which contains this VASA segment, competitively bound to Fbxo45 and rescued Par-4-mediated induction of cancer cell-specific apoptosis. Collectively, our findings identify a molecular decoy naturally generated during apoptosis that inhibits a ubiquitin ligase to overcome therapy resistance in tumors. .
原发性肿瘤通常是异质性的,由对治疗敏感和新出现的耐药癌细胞组成。有趣的是,在异质性肿瘤微环境中对治疗敏感的肿瘤进行治疗会导致耐药肿瘤细胞凋亡。在本研究中,我们鉴定出一种前列腺凋亡反应-4(Par-4)氨基末端片段(PAF),它是在肿瘤抑制蛋白Par-4被治疗诱导的半胱天冬酶切割后,由多种对治疗敏感的癌细胞释放出来的。PAF可诱导对治疗耐药的癌细胞凋亡并抑制肿瘤生长。Par-4的一个VASA片段介导其与泛素连接酶Fbxo45的结合和降解,导致Par-4促凋亡功能丧失。相反,包含该VASA片段的PAF竞争性地与Fbxo45结合,并挽救Par-4介导的癌细胞特异性凋亡诱导。总的来说,我们的研究结果鉴定出一种在凋亡过程中自然产生的分子诱饵,它可抑制泛素连接酶以克服肿瘤的治疗耐药性。